zigakibart

DRUG3 trials

Conditions

Glomerular DiseaseGlomerulonephritisGlomerulonephritis, IGAGlomerulopathyIgA NephropathyImmunoglobulin A NephropathyImmunoglobulin A Nephropathy (IgAN)Immunoglobulin Disease

Phase 2

A Study to Assess the Effects of Zigakibart on IgA Nephropathy.

RecruitingNCT07146906

Novartis PharmaceuticalsImmunoglobulin A Nephropathy (IgAN)

Start: 2026-03-26End: 2030-10-18Target: 32Updated: 2026-08-10

Phase 3

Atrasentan in Patients With IgA Nephropathy

Active, not recruitingNCT04573478

Novartis PharmaceuticalsIgA Nephropathy, Immunoglobulin A Nephropathy

Start: 2020-12-11End: 2028-04-14Updated: 2026-06-04

Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

RecruitingNCT06858319

Novartis PharmaceuticalsGlomerular Disease, Glomerulonephritis, Glomerulonephritis, IGA +5

Start: 2025-07-28End: 2031-06-25Target: 220Updated: 2026-08-17

2025-06-101 citations

The Global Kidney Patient Trials Network and the CAPTIVATE Platform Clinical Trial Design

JAMA Network Open2024-12-1110 citations

Atrasentan in Patients with IgA Nephropathy

New England Journal of Medicine2024-10-2559 citations

Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy.

2024-10-107 citations

WCN24-2099 BASELINE CHARACTERISTICS OF THE ALIGN TRIAL: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF ATRASENTAN IN PATIENTS WITH IGAN

Kidney International Reports2024-04-011 citations

Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study.

2023-02-0940 citations

zigakibart

Sponsors

Conditions

Phase 2

Phase 3

Related Papers